Quantcast

Latest Ampio Pharmaceuticals Inc. Stories

2014-04-02 08:33:12

Regulatory Clearance Enables Commercialization in Europe and other Key Markets GREENWOOD VILLAGE, Colo., April 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS(TM) Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in strategic...

2014-03-11 08:29:56

GREENWOOD VILLAGE, Colo., March 11, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial in details for a scheduled investor call, Thursday, March 13, 4:00 PM EDT. Participants are invited to dial in using the instructions as follows: Number and Participant Passcode: Participant Passcode: 606197 Int'l Toll: 719-785-1745 US/CAN Toll free: 888-471-3830 Questions can be emailed in advance to April Ramirez at aramirez@ampiopharma.com Access will...

2014-03-05 12:27:16

GREENWOOD VILLAGE, Colo., March 5, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the closing of its sale of 9,775,000 shares of common stock in an underwritten public offering. The total number of shares of common stock sold reflects the full exercise by the underwriters of their option to purchase an additional 1,275,000 shares of common stock. As a result, Ampio Pharmaceuticals, Inc. has received gross proceeds of approximately $68 million. Net...

2014-02-27 20:23:05

GREENWOOD VILLAGE, Colo., Feb. 27, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has priced an underwritten public offering of 8,500,000 shares of its common stock. The shares will be sold at a price to the public of $7.00 per share for gross proceeds of $59.5 million. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the...

2014-02-24 08:27:32

GREENWOOD VILLAGE, Colo., Feb. 24, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it intends to offer 8,000,000 shares of its common stock in a proposed underwritten public offering. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Ampio expects to grant the underwriters a 30-day option to purchase additional shares of...

2014-02-18 08:31:01

GREENWOOD VILLAGE, Colo., Feb. 18, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it has completed enrollment and dosing of 500 patient in the pivotal trial of Ampion((TM)) for the treatment of acute osteoarthritis of-the-knee (OAK). http://clinicaltrials.gov/ct2/show/NCT02024529?term=ampio&rank=1 (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained: "This phase III,...

2014-02-13 08:29:59

GREENWOOD VILLAGE, Colo., Feb. 13, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced preliminary biochemical analysis of samples of synovial fluid drawn from the index knee (treated knee) of a subset of patients who participated in the SPRING study. This synovial analysis, suggested by the FDA, tests the change in expression of signaling and structural proteins that arise from the treatment of the knee with either Ampion(TM) or the saline vehicle...

2014-02-04 08:28:44

GREENWOOD VILLAGE, Colo., Feb. 4, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio" or the "Company") today announced that the article reporting the results of its initial pivotal clinical trial of Ampion(TM) for the treatment of pain due to Osteoarthritis of the knee (OAK), was published in PLOS ONE, an international, rigorously peer-reviewed, open-access, online publication which covers primary research from any discipline within science and medicine, and is...

2014-01-15 08:28:06

Expected to create approximately 40 new jobs over next two years GREENWOOD VILLAGE, Colo., Jan. 15, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) held a groundbreaking ceremony on Friday, January 10th to announce the start of construction of its new state-of-the-art manufacturing facility for its lead drug candidate, Ampion(TM), for the treatment of patients afflicted with osteoarthritis of the knee. Located in the Denver Metro area, the facility is expected to be...

2014-01-13 08:27:33

GREENWOOD VILLAGE, Colo., Jan.13, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 500 patient Phase III pivotal trial of Ampion(TM) for the treatment for osteoarthritis of-the-knee (OAK) has received IRB approval and FDA IND clearance and that patients enrollment and treatments have commenced. http://clinicaltrials.gov/ct2/show/NCT02024529?term=ampio&rank=1 (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related